Las Vegas, NV -- (SBWIRE) -- 10/01/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), Sigma Labs Inc (OTCMKTS: SGLB), Nektar Therapeutics (NASDAQ:NKTR), Take-Two Interactive Software, Inc. (NASDAQ:TTWO)
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) managed to keep its gain at 8.84% on above-normal volume of 3.35M shares. The stock settled at $3.94 after floating in a range of $3.62 to $4.19. Its latest price has reached market capitalization of $329.08 million. Its 52-week range has been $1.49 to $5.95. ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer.
For How Long ZIOP will fight for Profitability? Read This Trend Analysis report
Sigma Labs Inc (OTCMKTS: SGLB) traded up on a volume of 4.12 million, higher than its standard daily volume. Shares have gained 9.47% to $0.104. Over the last twelve months, the stock has gained 593.33% and faced a worst price of $0.01. Renren Inc. operates a social networking Internet platform in the People?s Republic of China.
For How Long SGLB’s Gloss will Attract Investors? Find out via this report
Nektar Therapeutics (NASDAQ:NKTR) settled -0.91% lower at $10.44 on above-normal volume of 3.33M shares during the last trading day. The stock has its 12-month high at $14.47 and 52-week low price was $5.65. It traded in a range of $10.33 to $10.92 during the last trading day. Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology.
Will NKTR Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Take-Two Interactive Software, Inc. (NASDAQ:TTWO) was up on high volume, trading at a volume of 3.32 M versus its average daily volume of 1.98 million shares. At $18.17, the stock has attained market capitalization of 1.69 Billion. Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment for consumers worldwide. The company offers its products under the labels, including Rockstar Games and 2K.
Will TTWO Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)